News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Solvay SA Delays U.S. Filing For Psychosis Drug
October 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BRUSSELS, Sept 29 (Reuters) - Belgian drugs and chemicals maker Solvay's planned filing for U.S. approval for its psychosis drug Bifeprunox has been delayed until October, Solvay said on Friday.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
·
1 min read
·
Tristan Manalac
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
·
3 min read
·
Tristan Manalac
FDA
FDA Rejections: We Read 200 CRLs So You Don’t Have To
July 11, 2025
·
5 min read
·
Annalee Armstrong
